Novavax
- Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
- Total publications:1000 publications
Grant number: N/A
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$4,000,000Funder
Coalition for Epidemic Preparedness Innovations (CEPI)Principal Investigator
Gregory GlennResearch Location
United States of AmericaLead Research Institution
NovavaxResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Antigen is recombinant full-length S protein nanoparticles engineered in baculovirus and expressed in Sf9 insect cells; Adjuvant is saponin-based Matrix-M (raw material sourced from tree bark from source in Chile)Phase I safety and immunogenicity
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC